Shopping Cart 0
Cart Subtotal
USD 0

Achaogen Inc (AKAO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Achaogen Inc (Achaogen) is a biopharmaceutical company that discovers, develops and commercializes novel anti bacterials for the treatment of multi-drug resistant and gram-negative infections. The company offers plazomicin for the treatment of serious bacterial infections including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae. Its pipeline products include C-scape, novel aminoglycoside, and others. Achaogen's C-Scape is a combination of an approved beta-lactam and an approved beta-lactamase inhibitor that can treat patients with complex urinary tract infections due to MDR pathogens. The company collaborates with antibacterial drug development companies and academic researchers in the field of antibiotic pharmacology. Achaogen is headquartered in San Francisco, California, the US.

Achaogen Inc (AKAO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Achaogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Achaogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Achaogen Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Achaogen Raises USD 19 Million In Venture Financing 11

Partnerships 12

Achaogen Enters into Agreement with Microgenics 12

Licensing Agreements 13

Achaogen Enters into Licensing Agreement with Crystal Bioscience 13

Achaogen Enters into Licensing Agreement with Trianni 14

Equity Offering 15

Achaogen to Raise up to USD50 Million in Public Offering of Shares 15

Achaogen Raises USD112.5 Million in Public Offering of Shares 16

Achaogen to Raise USD10 Million in Private Placement of Shares 18

Achaogen Receives USD5.3 Million in Public Offering of Shares 19

Achaogen Raises USD101 Million in Public Offering of Shares 20

Achaogen Raises USD25 Million in Private Placement of Shares 22

Achaogen Completes IPO For USD 82.8 Million 24

Achaogen Inc-Key Competitors 25

Achaogen Inc-Key Employees 26

Achaogen Inc-Locations And Subsidiaries 27

Head Office 27

Recent Developments 28

Financial Announcements 28

Aug 06, 2018: Achaogen reports second quarter 2018 financial results and provides corporate update 28

May 04, 2018: Achaogen Reports First Quarter 2018 Financial Results and Provides Corporate Update 30

Feb 27, 2018: Achaogen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 31

Nov 08, 2017: Achaogen Reports Third Quarter 2017 Financial Results and Provides Corporate Update 33

Aug 03, 2017: Achaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update 34

May 08, 2017: Achaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update 36

Mar 14, 2017: Achaogen Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 38

Corporate Communications 40

Dec 11, 2017: Achaogen Appoints Blake Wise Chief Executive Officer 40

Sep 18, 2017: Achaogen Adds Liz Bhatt as Chief Business Officer 41

Jul 13, 2017: Achaogen Appoints Dr. Karen Bernstein to its Board of Directors 42

Feb 27, 2017: Achaogen Adds Janet Dorling as Chief Commercial Officer 43

Feb 23, 2017: Achaogen Announces Leadership Promotions 44

Jan 05, 2017: Achaogen appoints new board member 45

Government and Public Interest 46

May 05, 2017: Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria 46

Product News 47

07/25/2017: Achaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant Infections 47

Mar 01, 2017: Achaogen Highlights Emerging Pipeline of Antibacterials Including a new Orally-Administered Antibiotic Clinical Candidate at Company's R&D Day 48

Clinical Trials 49

Jan 02, 2018: Achaogen Announces Positive Top-Line Results from First Clinical Trial of Orally-Administered Antibacterial Candidate C-Scape 49

Sep 28, 2017: Achaogen Awarded up to USD 18 Million Contract by BARDA to Support Development of Orally-Administered Antibacterial Candidate C-Scape 51

Jun 01, 2017: Achaogen Initiates C-Scape Clinical Development Program with Phase 1 Study of Orally-Administered Antibacterial Candidate 52

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53


List Of Figure

List of Figures

Achaogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Achaogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Achaogen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Achaogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Achaogen Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Achaogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Achaogen Raises USD 19 Million In Venture Financing 11

Achaogen Enters into Agreement with Microgenics 12

Achaogen Enters into Licensing Agreement with Crystal Bioscience 13

Achaogen Enters into Licensing Agreement with Trianni 14

Achaogen to Raise up to USD50 Million in Public Offering of Shares 15

Achaogen Raises USD112.5 Million in Public Offering of Shares 16

Achaogen to Raise USD10 Million in Private Placement of Shares 18

Achaogen Receives USD5.3 Million in Public Offering of Shares 19

Achaogen Raises USD101 Million in Public Offering of Shares 20

Achaogen Raises USD25 Million in Private Placement of Shares 22

Achaogen Completes IPO For USD 82.8 Million 24

Achaogen Inc, Key Competitors 25

Achaogen Inc, Key Employees 26

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Achaogen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Achaogen Inc (Achaogen) is a biopharmaceutical company that discovers, develops and commercializes novel anti bacterials for the treatment of multi-drug resistant and gram-negative infections. The company offers plazomicin for the treatment of serious bacterial infections including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae. Its pipeline products include C-scape, novel aminoglycoside, and others. Achaogen's C-Scape is a combination of an approved beta-lactam and an approved beta-lactamase inhibitor that can treat patients with complex urinary tract infections due to MDR pathogens. The company collaborates with antibacterial drug development companies and academic researchers in the field of antibiotic pharmacology. Achaogen is headquartered in San Francisco, California, the US.

Achaogen Inc (AKAO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Achaogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Achaogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Achaogen Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Achaogen Raises USD 19 Million In Venture Financing 11

Partnerships 12

Achaogen Enters into Agreement with Microgenics 12

Licensing Agreements 13

Achaogen Enters into Licensing Agreement with Crystal Bioscience 13

Achaogen Enters into Licensing Agreement with Trianni 14

Equity Offering 15

Achaogen to Raise up to USD50 Million in Public Offering of Shares 15

Achaogen Raises USD112.5 Million in Public Offering of Shares 16

Achaogen to Raise USD10 Million in Private Placement of Shares 18

Achaogen Receives USD5.3 Million in Public Offering of Shares 19

Achaogen Raises USD101 Million in Public Offering of Shares 20

Achaogen Raises USD25 Million in Private Placement of Shares 22

Achaogen Completes IPO For USD 82.8 Million 24

Achaogen Inc-Key Competitors 25

Achaogen Inc-Key Employees 26

Achaogen Inc-Locations And Subsidiaries 27

Head Office 27

Recent Developments 28

Financial Announcements 28

Aug 06, 2018: Achaogen reports second quarter 2018 financial results and provides corporate update 28

May 04, 2018: Achaogen Reports First Quarter 2018 Financial Results and Provides Corporate Update 30

Feb 27, 2018: Achaogen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 31

Nov 08, 2017: Achaogen Reports Third Quarter 2017 Financial Results and Provides Corporate Update 33

Aug 03, 2017: Achaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update 34

May 08, 2017: Achaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update 36

Mar 14, 2017: Achaogen Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 38

Corporate Communications 40

Dec 11, 2017: Achaogen Appoints Blake Wise Chief Executive Officer 40

Sep 18, 2017: Achaogen Adds Liz Bhatt as Chief Business Officer 41

Jul 13, 2017: Achaogen Appoints Dr. Karen Bernstein to its Board of Directors 42

Feb 27, 2017: Achaogen Adds Janet Dorling as Chief Commercial Officer 43

Feb 23, 2017: Achaogen Announces Leadership Promotions 44

Jan 05, 2017: Achaogen appoints new board member 45

Government and Public Interest 46

May 05, 2017: Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria 46

Product News 47

07/25/2017: Achaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant Infections 47

Mar 01, 2017: Achaogen Highlights Emerging Pipeline of Antibacterials Including a new Orally-Administered Antibiotic Clinical Candidate at Company's R&D Day 48

Clinical Trials 49

Jan 02, 2018: Achaogen Announces Positive Top-Line Results from First Clinical Trial of Orally-Administered Antibacterial Candidate C-Scape 49

Sep 28, 2017: Achaogen Awarded up to USD 18 Million Contract by BARDA to Support Development of Orally-Administered Antibacterial Candidate C-Scape 51

Jun 01, 2017: Achaogen Initiates C-Scape Clinical Development Program with Phase 1 Study of Orally-Administered Antibacterial Candidate 52

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53


List Of Figure

List of Figures

Achaogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Achaogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Achaogen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Achaogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Achaogen Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Achaogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Achaogen Raises USD 19 Million In Venture Financing 11

Achaogen Enters into Agreement with Microgenics 12

Achaogen Enters into Licensing Agreement with Crystal Bioscience 13

Achaogen Enters into Licensing Agreement with Trianni 14

Achaogen to Raise up to USD50 Million in Public Offering of Shares 15

Achaogen Raises USD112.5 Million in Public Offering of Shares 16

Achaogen to Raise USD10 Million in Private Placement of Shares 18

Achaogen Receives USD5.3 Million in Public Offering of Shares 19

Achaogen Raises USD101 Million in Public Offering of Shares 20

Achaogen Raises USD25 Million in Private Placement of Shares 22

Achaogen Completes IPO For USD 82.8 Million 24

Achaogen Inc, Key Competitors 25

Achaogen Inc, Key Employees 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Achaogen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.